• TYBR Health

  Participated · Series A · Jul 2026

  TYBR Health develops extracellular matrix-based products intended to protect healing tissues following surgery, centered on its FDA-cleared B3 GEL® System. B3 GEL® is a flowable extracellular matrix hydrogel designed to conform to complex three-dimensional anatomy and be rapidly applied within existing surgical workflows. Since launch, the system has been used in hand, wrist, shoulder, foot and ankle, and sports medicine procedures, with early adoption by surgeons seeking straightforward intraoperative tissue protection. The company says the product adheres where applied and forms a protective barrier through the healing window. TYBR Health plans to use the Series A proceeds to expand commercial access, broaden indications, and run clinical studies evaluating tissue protection during orthopedic surgery. The company is headquartered in Houston, Texas.

• Icarus Medical

  Participated · Series A · Jun 2026

  Icarus Medical develops a new class of orthopedic bracing technologies that combine biomechanics, software, and additive manufacturing to address osteoarthritis, post-operative recovery, neurological conditions, and complex lower-extremity mobility challenges. Key products include the Ascender Knee Brace for patellofemoral and multicompartment osteoarthritis and the Adonis Joint Distraction Knee Brace for unicompartmental osteoarthritis. The company designs and manufactures its products in Charlottesville, Virginia, and plans to expand manufacturing capacity as part of its growth strategy. Icarus intends to advance clinical validation of its devices while accelerating commercialization across the U.S. and hiring additional personnel. Its recent recognition includes placement on the Inc. 5000 list for 1,283% three-year growth and the 2026 CBIC Startup of the Year Award.

No current team members are available.